BIOMAT Database Logo BIOMAT Database Logo

Differences in absorption of BAY u 3405 along the human gastrointestinal tract. 1992

U Fuhr, and J Hoyer, and W Ritter, and A H Staib
Dept. of Clinical Pharmacology, University Hospital, Frankfurt/M, Germany.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008297 Male Males
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D002227 Carbazoles Benzo-indoles similar to CARBOLINES which are pyrido-indoles. In plants, carbazoles are derived from indole and form some of the INDOLE ALKALOIDS.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug

Related Publications

U Fuhr, and J Hoyer, and W Ritter, and A H Staib
Absorption of ipsapirone along the human gastrointestinal tract.
July 1994, British journal of clinical pharmacology,
U Fuhr, and J Hoyer, and W Ritter, and A H Staib
Bay U 3405 inhibits cerebral vasospasm induced by authentic thromboxane A2.
December 1990, Stroke,
U Fuhr, and J Hoyer, and W Ritter, and A H Staib
Characterization of Bay U 3405, a novel thromboxane A2/endoperoxide receptor antagonist.
December 1990, Stroke,
U Fuhr, and J Hoyer, and W Ritter, and A H Staib
Receptor binding properties of the new and specific thromboxane receptor antagonist Bay U 3405.
January 1992, Agents and actions. Supplements,
U Fuhr, and J Hoyer, and W Ritter, and A H Staib
Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease.
December 1990, Stroke,
U Fuhr, and J Hoyer, and W Ritter, and A H Staib
Improved coronary thrombolysis by tissue-type plasminogen activator in the presence of BAY U 3405.
June 1991, European journal of pharmacology,
U Fuhr, and J Hoyer, and W Ritter, and A H Staib
Protective effects of BAY U 3405, a thromboxane A2 receptor antagonist, in endotoxin shock.
January 1994, Pharmacological research,
U Fuhr, and J Hoyer, and W Ritter, and A H Staib
Effect of BAY U 3405, a new thromboxane antagonist, on sudden death in rabbits.
January 1991, Journal of lipid mediators,
U Fuhr, and J Hoyer, and W Ritter, and A H Staib
Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule).
November 1989, The American journal of medicine,
U Fuhr, and J Hoyer, and W Ritter, and A H Staib
Digestion and absorption of protein along ovine gastrointestinal tract.
July 1985, Journal of dairy science,
Copied contents to your clipboard!